方正证券：医药生物业新一轮上行已经开始重视早研CRO产业外包新趋势

智通财经

10/31

智通财经APP获悉，方正证券发布研报称，医药生物行业景气度进入新一轮上行周期，出海订单加速释放且处于行业成长早期，向上动能强劲，坚定看好具备强出海能力的生物品类上游公司;CXO板块中，早研产业链具备极大发展空间，创新药出海具备历史性机遇。方正证券主要观点如下：早研CRO:早研CRO产业转移正当时，实验猴景气度稳中有升临床前及安评订单逐步回暖，该行认为新一轮上行周期或将受益于：1)创新药BD出海热潮...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579895054"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579895054\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579895054?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-31 09:34","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2579895054","market":"hk","top_or_hot":-1,"title":"方正证券：医药生物业新一轮上行已经开始 重视早研CRO产业外包新趋势","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，方正证券发布研报称，医药生物行业景气度进入新一轮上行周期，出海订单加速释放且处于行业成长早期，向上动能强劲，坚定看好具备强出海能力的生物品类上游公司;CXO板块中，早研产业链具备极大发展空间，创新药出海具备历史性机遇。方正证券主要观点如下：早研CRO:早研CRO产业转移正当时，实验猴景气度稳中有升临床前及安评订单逐步回暖，该行认为新一轮上行周期或将受益于：1)创新药BD出海热潮...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103109460894e68092&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>方正证券：医药生物业新一轮上行已经开始 重视早研CRO产业外包新趋势</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n方正证券：医药生物业新一轮上行已经开始 重视早研CRO产业外包新趋势\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-31 09:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103109460894e68092&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，方正证券发布研报称，医药生物行业景气度进入新一轮上行周期，出海订单加速释放且处于行业成长早期，向上动能强劲，坚定看好具备强出海能力的生物品类上游公司;CXO板块中，早研产业链具备极大发展空间，创新药出海具备历史性机遇。方正证券主要观点如下：早研CRO:早研CRO产业转移正当时，实验猴景气度稳中有升临床前及安评订单逐步回暖，该行认为新一轮上行周期或将受益于：1)创新药BD出海热潮...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103109460894e68092&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103109460894e68092&s=b","article_id":"2579895054","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103109460894e68092&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2579895054","pubTimestamp":1761874495,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"方正证券主要观点如下：早研CRO:早研CRO产业转移正当时，实验猴景气度稳中有升临床前及安评订单逐步回暖，该行认为新一轮上行周期或将受益于：1)创新药BD出海热潮下，国内早研产业链优势得到重视及认可，因此海外早研产业链有望渐向国内转移;2)海外进入降息周期后，海外药企研发需求逐渐回暖。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK1576":"医药外包概念","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1161":"生物科技","BK1574":"生物医药B类股","02359":"药明康德","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0052750758.USD":"富兰克林中国基金A Acc","06127":"昭衍新药","06978":"永泰生物-B","BK1141":"生命科学工具和服务","LU1046422090.SGD":"Fidelity Pacific A-SGD"},"translate_title":"Founder Securities: A new round of upward trend in pharmaceutical and biological properties has begun to pay attention to early research on new trends in CRO industry outsourcing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02359":0.9,"06127":0.9,"06978":0.72},"content_text":"智通财经APP获悉，方正证券发布研报称，医药生物行业景气度进入新一轮上行周期，出海订单加速释放且处于行业成长早期，向上动能强劲，坚定看好具备强出海能力的生物品类上游公司;CXO板块中，早研产业链具备极大发展空间，创新药出海具备历史性机遇。方正证券主要观点如下：早研CRO:早研CRO产业转移正当时，实验猴景气度稳中有升临床前及安评订单逐步回暖，该行认为新一轮上行周期或将受益于：1)创新药BD出海热潮下，国内早研产业链优势(质量+效率+成本)得到重视及认可，因此海外早研产业链有望渐向国内转移;2)海外进入降息周期后，海外药企研发需求逐渐回暖。因此建议关注细分领域龙头益诺思、昭衍新药，以及临床前一体化CRO龙头康龙化成(错配情况或将持续，实验猴价格短期有望稳中有升。H)、药明康德等。此外，安评领域中实验猴作为战略资源，该行认为短期供需错配情况或将持续，实验猴价格短期有望稳中有升。生科上游：国内生物品类恢复较快，行业出海方兴未艾2025H1生物试剂包括培养基、重组蛋白以及分子砌块、色谱填料增速加快，该行认为主要受益于：1)国内创新药出海带来结构性回暖;2)行业出海增速较快，因此该行继续看好上游产品出海。一方面海外市场空间广阔，且药企降本需求下，国产品牌具有性价比;另外，国内创新药BD带来的“水”渐流入早期研发，建议关注上游中生物药产业链相关的方向，且具备出海能力的企业，包括百普赛斯、百奥赛图浦迈、皓元医药等。临床CRO：行业拐点或将至，SMO率先回暖国内需求有望逐渐改善，SMO订单率先回暖。该行预计随着创新药融资回暖，IND有望陆续推进临床带动项目数增长，量增价稳下整体订单有望回暖。其次供给侧格局持续优化，头部企业有望持续提升份额。建议关注临床CRO龙头泰格医药、诺思格等。CDMO板块：新分子赛道潜力巨大，相关供应商业绩弹性可期中报整体业绩表现优异，多肽&ADC等细分赛道增速领先。短期来看，多肽及ADC赛道有望保持高景气度;长期来看，其它新分子包括小核酸等仍具发展潜力。建议关注CDMO龙头企业包括凯莱英、药明康德等，依托小分子业务稳健，新分子业务快速发展，业绩弹性可期。风险提示：降息及创新药BD带来的早期研发需求不及预期风险、地缘政治下政策波动风险、CDMO下游商业化产品销售不及预期风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}

方正证券：医药生物业新一轮上行已经开始 重视早研CRO产业外包新趋势

热议股票

方正证券：医药生物业新一轮上行已经开始重视早研CRO产业外包新趋势